|Articles|November 17, 2021
Daily OTC Pearl: Aspercreme 10%
Author(s)Saro Arakelians, PharmD
Trolamine salicylate is a pain-relieving compound closely related to aspirin, a nonsteroidal anti-inflammatory drug.
Advertisement
OTC/Lifestyle Pearl of the Day: Aspercreme 10%
Indication: Trolamine
Insight:
- Aspercreme belongs to a class of drugs known as
salicylates . - Trolamine salicylate is a pain-relieving compound closely related to aspirin, a nonsteroidal anti-inflammatory drug.
- Aspercreme is for use on the
skin only. Patients should know to not get this medication in theireyes , inside the nose ormouth , or inside thevagina . - Apply the medication to the affected area no more than 3 to 4 times a day. Rub in gently and thoroughly. After applying the medication,
wash hands . - Do not apply this medication on broken or irritated
skin . Do not bandage or tightly wrap the affected area or apply heat to the area. - Adverse effects may include blistering/peeling/redness/irritation at the application site,
nausea /vomiting , andringing in the ears . - Aspercreme products contain the maximum percentage of lidocaine currently approved for OTC use.Versions containing lidocaine include Lidocaine cream, Lidocaine patch, Lidocaine spray, and Lidocaine liquid roll-on.
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
3
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
4
FDA Approves Bosaya and Aukelso, Biosimilars to Reference Denosumab
5